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  The pharmacokinetics and dosage regimen of norfloxa-
cin-glycine acetate (NFLXGA) was investigated in pigs af-
ter a single intravenous (i.v.) or oral (p.o.) administration 
at a dosage of 7.2 mg/kg body weight. After both i.v. and 
p.o. administration, plasma drug concentrations were best 
fitted to an open two-compartment model with a rapid dis-
tribution phase. After i.v. administration of NFLXGA, the 
distribution (t1/2α) and elimination half-life (t1/2β) were 0.36 
± 0.07 h and 7.42 ± 3.55 h, respectively. The volume of dis-
tribution  of  NFLXGA  at  steady  state  (Vdss)  was  4.66  ± 
1.39 l/kg. After p.o. administration of NFLXGA, the max-
imal absorption concentration (Cmax) was 0.43 ±  0.06 µg/ 
ml at 1.36 ±  0.39 h (Tmax). The mean absorption (t1/2ka) and 
elimination half-life (t1/2β) of NFLXGA were 0.78 ±  0.27 h 
and 7.13 ± 1.41 h, respectively. The mean systemic bioavai-
lability (F) after p.o. administration was 31.10 ±  15.16%. 
We suggest that the optimal dosage calculated from the 
pharmacokinetic parameters is 5.01 mg/kg per day i.v. or 
16.12 mg/kg per day p.o.
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Introduction 
  Fluoroquinolones are a group of synthetic antimicrobial 
agents that are highly potent and exhibit a broad spectrum 
of activity against a variety of mycoplasmas and 
Gram-negative bacteria, and some Gram-positive bacteria 
[5,11]. Norfloxacin is one of the first modern fluo-
roquinolone antimicrobial agents featuring a fluorine atom 
in position 6 and a piperazinyl or pyrrolidinyl substituent in 
position 7 of the quinoline nucleus [24]. Norfloxacin-gly-
cine acetate (NFLXGA), a newly formulated norfloxacin 
that exerts its antibacterial effect by breaking double- 
stranded DNA [15], has been widely used for both pre-
vention and therapeutic treatment of bacterial infections in 
humans and animals.
  The quinolones bear both an acidic group (carboxylic 
acid) and a basic group (tertiary amine). This association 
gives them amphoteric properties. Their lipid solubility is 
low, except between pH 6 and 8. Within this range they 
have low water solubility and are prone to precipitate under 
more acidic conditions [22]. In order to overcome this 
problem, we made a new salt form, NFLXGA [15]. 
NFLXGA has a high solubility in water and it did not pre-
cipitate under acidic conditions ranging from pH 4 to 7 
over a 6 month period (data not shown). 
  The pharmacokinetics of norfloxacin have been studied 
in various animals including dogs [4], pigs [2], chickens 
[3,12], calves [9] and laboratory animals [7]. The optimal 
dose range of the drug has been suggested to be 5-22 mg/kg 
body weight in these animals, on the basis of the minimal 
inhibition concentration (MIC) and the maximal nor-
floxacin concentration (Cmax) in blood following drug 
administration. In our previous studies, we reported the 
pharmacokinetics of NFLXGA in flounder [16], horse [17] 
and rabbits [18].
  In recent years, it has been suggested that the optimal dos-
age should be set in terms of pharmacokinetic-pharmaco-
dynamic (PK/PD) relationships [20]. The pharmacoki-
netics of NFLXGA after oral administration has not been 
established in pigs. Therefore, the present study was de-
signed to provide the clinical pharmacokinetics of nor-
floxacin following intravenous (i.v.) and oral (p.o.) admin-
istration in pigs and to determine the optimal dosage on the 
basis of the PK/PD parameters. 354    Zhi-Qiang Chang et al.
Materials and Methods
Animals
  Six male pigs weighing 60 ± 5 kg were used in this study. 
The animals were reared and maintained at the Chungnam 
National University Farm. They were housed indoors and 
fed with a drug-free commercial pellet diet and water ad 
libitum. The Animal Ethics Committee of the Veterinary 
Faculty at Chungnam National University approved the 
study. 
Treatment
  The study was carried out in a two-period crossover man-
ner with animals randomly divided into two groups of three 
pigs. In period 1, three pigs received NFLXGA (Daesung 
Microbiologicals, Korea) i.v. over 40 sec at a dose of 7.2 
mg/kg whilst three other pigs received the same dose of 
norfloxacin p.o. The formulation of NFLXGA consisted of 
norfloxacin (0.75 parts), acetic acid (0.15 parts) and gly-
cine (0.1 part) based on mass. After an interval of 21 days, 
the treatments were reversed, i.e., pigs that previously re-
ceived NFLXGA i.v. were administered the drug p.o., and 
those that initially received NFLXGA p.o. were ad-
ministered the drug i.v. in period 2.
Blood sampling
  5 ml blood samples were collected from the jugular vein 
directly into tubes before (0 h) and 0.25, 0.5, 1, 2, 4, 6, 8, 
12, 24 h following drug administration. The serum samples 
were separated by centrifugation at 8,000 g for 5 min and 
were stored at 򰠏70°C (for up to one week) until determi-
nation of the norfloxacin concentration.
Norfloxacin analysis
  The amount of norfloxacin was measured by high per-
formance liquid chromatography (HPLC) using the meth-
od described previously by Park et al. [18]. Briefly, 1 ml se-
rum was deproteinated with 1 ml 20% cold trichloroacetic 
acid in methanol. The mixture was vortexed for 1 min and 
centrifuged for 5 min at 15,000 g. 20 µl of each supernatant 
was injected into a HPLC system equipped with a reverse 
phase column (particle size 10 µm; 30 cm × 3.6 mm) and 
measured at a UV wavelength of 278 nm. The mobile 
phase was composed of 20% citric acid, 0.01 M phosphate 
buffer containing 1 mM heptane sulfonic acid and acetoni-
trile (800 : 1 : 200 = v/v/v) and the pH was adjusted to 3.0 
with phosphoric acid. The validated limit of norfloxacin 
quantification for this method was 0.05 µg/ml. The ex-
traction recoveries were greater than 80% and the co-
efficient of variation was less than 10% indicating high 
reproducibility.
Data analysis and dosage regimen
  All pharmacokinetic parameters were derived using the 
WinNonlin software package (SCI, USA). The individual 
serum concentration data following administration were 
analyzed by nonlinear least-squares regression analysis. 
The best fit was achieved with a two-compartment model 
for both i.v. and p.o. administration. As a result, the serum 
concentration time curves of norfloxacin after a single i.v. 
or p.o. dose were fitted to the following equations: 
  Ci.v. = Ae
-αt + Be
-βt 
  Cp.o. = Ae
-αt + Be
-βt 򰠏 Ce
-kat 
where (Ci.v.) and (Cp.o.) are the concentrations in serum at 
time t after i.v. and p.o. administration respectively; A and 
B are the zero-time serum drug concentration intercepts of 
biphasic i.v. and p.o. disposition curves; C is the zero-time 
serum drug concentration intercept of the absorption phase 
after p.o. administration; e is the base of the natural loga-
rithm; α is the hybrid rate constant of the slope of dis-
tribution phase; β is the hybrid rate constant of the slope of 
elimination phase; and ka is the hybrid rate constant of the 
slope of absorption. Following p.o. administration, the bio-
availability F was calculated according to the equation:
  F (%) = (AUCp.o./AUCi.v.) × (βp.o/βi.v.) × 100%. 
The equations used for calculating dosage in pigs were as 
follows: 
  Doseiv = Cave × Clearance = Cave × Vdss × (0.693/t1/2β); 
  Dosepo = Doseiv/F.
Results
  The concentrations-time curves of norfloxacin following 
single i.v. and p.o. administration of 7.2 mg NFLXGA/kg 
body weight to pigs are shown in Fig. 1. Concentration ver-
sus time data were analyzed to achieve the best fit with a 
two-compartment model after both routes of admin-
istration in all pigs. The pharmacokinetic parameters are 
summarized in Table 1. 
  15 min after i.v. and p.o. administration of NFLXGA, the 
serum concentrations of norfloxacin were 5.22 ± 1.40 µg/ 
ml and 0.18 ± 0.08 µg/ml, respectively (Fig. 1.). Therea-
fter, serum norfloxacin concentrations were maintained in 
all animals for up to 24 h at more than 0.05 ± 0.03 µg/ml 
(i.v.) and 0.03 ± 0.02 µg/ml (p.o.). The distribution rate 
constant was 1.96 ± 0.36 h after i.v. administration with a 
distribution half-life (t1/2α) of 0.36 ± 0.07 h.
  The serum concentration of norfloxacin reached a max-
imum level (Cmax) of 0.43 ± 0.06 µg/ml at 1.36 ± 0.39 h 
(Tmax), and the absorption half-life (t1/2ka) was 0.78 ± 0.27 h 
after p.o. administration in pigs. The mean elimination 
half-lives (t1/2β) after i.v. and p.o. administration were 7.42 
± 3.55 h and 7.13 ± 1.41 h respectively, and there are no sig-
nificant differences. The systemic bioavailability (F) after 
oral administration of NFLXGA was 31.10 ± 15.16%.Pharmacokinetics of norfloxacin in pigs    355
Table 1. Parmacokinetic parameters that describe the disposition 
of norfloxacin-glycine acetate (7.2 mg/kg body weight) after in-
travenous and oral administration in six pigs
Parame-
  ters
Unit
I.V. administration
(Mean ± SD)
P.O. administration
(Mean ± SD)
A
B
α
β
AUC
t1/2ka
t1/2α
t1/2β
k12
k21
Cmax
Tmax
CLB
AUMC
VdSS
F
µg/ml
µg/ml
/h
/h
µg/mlㆍh
h
h
h
/h
/h
µg/ml
h
l/kg/h
µgㆍh
2/ml
l/kg
%
7.85 ± 2.75
0.58 ± 0.16
1.96 ± 0.36
0.12 ± 0.06
9.66 ± 2.55
−
0.36 ± 0.07
7.42 ± 3.55
0.93 ± 0.17
0.26 ± 0.16
−
−
  0.8 ± 0.26
68.17 ± 49.08
4.66 ± 1.39
−
  41.2 ± 14.09
0.24 ± 0.10
0.99 ± 0.38
0.09 ± 0.03
3.47 ± 1.11
0.78 ± 0.27
0.79 ± 0.29
7.13 ± 1.41
0.47 ± 0.21
0.30 ± 0.18
0.43 ± 0.06
1.36 ± 0.39
−
−
−
31.10 ± 15.16
The results were expressed as mean ± SD (n = 6). A and B, zero-time 
serum concentration intercepts of biphasic i.v. and p.o. disposition 
curves; α, hybrid rate constants of the slope of distribution; β, hybrid 
rate constants of the slope of elimination; AUC, the area under the 
concentration-time curves; t1/2ka, the absorption half-life; t1/2α, the dis-
tribution half-life; t1/2β, the elimination half-life; k12 and k21, first-order
transfer rate constants for drug distribution from the central compart-
ment to the peripheral compartment and from the peripheral compart-
ment to the central compartment; Cmax, maximum concentration; Tmax,
time to reach the maximum concentration; MRT, mean residence 
time; CLB, serum clearance; AUMC, total area under the moment 
curve; VdSS, steady-state volume of distribution; F, bioavailability.
Fig. 1. Serum concentration of norfloxacin following i.v. (▲) or 
p.o. (■) administration of 7.2 mg NFLXGA per kg body weight 
(n = 6).
Discussion
  The mean elimination half-life (t1/2β) after i.v. admin-
istration of NFLXGA in the present study was estimated to 
be 7.42 ± 3.55 h. This is longer than the t1/2β in rabbits (3.93 
± 1.54 h) [18] or horses (5.44 ± 1.36 h) [17], and also longer 
than that found in the previous studies of norfloxacin in 
pigs (3.65 ± 0.16 h) [2] and dogs (3.56 h) [4], and that of 
norfloxacin nicotinate in swine (2.1 h) [21] and donkeys 
(3.51 ± 0.49 h) [13]. It is however a little shorter than that 
seen in chickens (8.0 ± 0.3 h) [3]. The volume of dis-
tribution at steady state (VdSS, 4.66 ± 1.39 l/kg) was higher 
than the previously reported value (2.21 ± 0.21 l/kg) [2], 
and the ratio of k12 and k21 was 3.58. All of these findings 
suggested that the drug was well distributed and retained in 
the tissues. After p.o. administration of NFLXGA, the 
mean elimination half-life (t1/2β) was 7.13 ± 1.41 h, similar 
to that obtained after i.v. administration. It has been re-
ported that the systemic bioavailability (F) of norfloxacin 
is only 30 to 40% after p.o. administration [14]. In the pres-
ent study, F was calculated to be about 31.10%, which is 
lower than the values determined in rabbits (40%) [18], and 
in broiler chickens (57.0%) [3], but is significantly higher 
than the oral bioavailability of norfloxacin nicotinate in 
donkeys with F values of 9.6% and 6.4% for the 10 and 20 
mg/kg doses respectively [13]. In pigs, however we could 
not find the optimal dosage using PK and PD parameters.
  The optimal dosage of drug can be determined with the 
equation provided by Toutain et al. [22], which is related to 
PK and PD parameters. In addition, Schentag stated pre-
viously that the AUC/MIC (AUIC) ratio of quinolones 
should be more than 125 to prevent selective pressure that 
leads to the overgrowth of resistant bacterial sub-pop-
ulations [20]. The MIC of norfloxacin has been shown to 
be below 0.12 µg/ml for Escherichia coli, Salmonella spp., 
Klebsiella pneumonia, Klebsiella oxytoca and Proteus vul-
garis [13]. Therefore, a desired average serum norfloxacin 
concentration of 0.48 µg/ml was selected by quadrupling 
the average MIC values in the present study. We suggest 
that the appropriate dosage of 5.01 mg/kg for i.v. and 16.12 
mg/kg for p.o. per day or 2.51 mg/kg for i.v. and 8.06 
mg/kg for p.o. per 12 h would provide a serum concen-
tration in pigs high enough to inhibit bacteria with a MIC 
less than 0.12 µg/ml. However, NFLXGA should not be 
considered the drug of choice for pigs infected with patho-
genic bacteria, such as Streptococcus spp. (MIC, 6.25 µg/ 
ml), Staphylococcus spp. (MIC, 1.56 µg/ml), Rhodoco-
ccus spp. (MIC, 6.26 µg/ml), and Bordetella spp. (MIC, 
3.12 µg/ml) showing more than 0.25 µg/ml of MIC [13,19].
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